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Human cytosolic sulfotransferases (SULT) 2A1 is the main enzyme involved in the sulfate
conjugation of dehydroepiandrosterone, a weak androgen, and the main androgen pre-
cursor, whereas estrogens are mainly conjugated by SULT1A1. Here we have identified
a copy number variation (CNV) polymorphism in the SULT2A1 gene in a Swedish popula-
tion including healthy men (N =30). Moreover, the CNV of SULT1A1 and SULT2A1 was
further characterized in relation to urinary levels of androgen sulfate metabolites before
and after an intramuscular dose of 500 mg testosterone enanthate. Individuals expressing
two or more CNVs excrete 80 and 40% higher levels of DHEAS (p=0.02) and andros-
teroneS (p=0.01), respectively as compared to individuals with one gene copy. The mean
area under the urine concentration time-curve from time 0 (prior to the administration of
500 mg testosterone) to 15 days post dose values were 80% higher for DHEAS (p=0.046)
and testosteroneS (p=0.019) in individuals with two and three SULT2A1 gene copies as
compared to individuals with one gene copy. The SULT1A1 CNV on the other hand did not
affect the sulfation activity toward the androgens. In conclusion our results indicate that
functional CNV polymorphisms in SULT2A1 and SULT1A1 are common in a Swedish pop-
ulation and that SULT2A1 CNV is associated with the urinary concentrations of androgen
sulfate metabolites.
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INTRODUCTION
Human cytosolic sulfotransferases (SULT) enzymes catalyze the
sulfate conjugations of many xenobiotics and endogenous com-
pounds such as hormones. These reactions result in increased
water solubility and enhanced urinary excretion of the con-
jugates. To date, 12 human SULT genes have been identified.
Among these SULT1A1 (also known as P-PST) is an enzyme
that has been well studied in relation to hormone related dis-
ease and detoxification of polycyclic aromatic hydrocarbons (1,
2). Another SULT member SULT2A1 (also known as DHEA ST)
is highly expressed in human liver and catalyzes the sulfation
of dehydroepiandrosterone (DHEA), the major steroid precur-
sor in humans (3, 4). DHEA itself is a weak androgen which
is converted into more active androgens in peripheral tissues
(5, 6).
Large inter-individual variations in circulatory levels of DHEAS
have been observed. Three SULT2A1 single nucleotide polymor-
phisms altering the amino acid sequence have been identified and
associated with altered SULT2A1 activity and DHEA:DHEAS ratio
in the circulation (7). Circulatory DHEAS is considered to repre-
sent the androgen pool and high concentration of DHEAS has
been associated with diseases and disorders such, i.e., PCOS, can-
cer, and obesity (8, 9). In addition, the urinary concentration of
DHEAS, as well as other androgen sulfates vary manifold between
individuals (10–12). This large inter-individual variation in uri-
nary excretion rate may be due to genetic variation in SULT
enzymes; however this has not been studied.
A copy number variation (CNV) polymorphism has been iden-
tified in SULT1A1. It was shown that individuals display between
one and five SULT1A1 gene copies and the number of gene copies
have been associated with the enzyme activity (13). Recently it was
found that SULT2A1 may exist in different CNVs (15). However,
there are no studies confirming this CNV in a human population.
CNV in other phase II hormone conjugating enzymes, i.e., uridine
diphosphate-glucuronyltransferases (UGTs) has been well charac-
terized (14). We have previously shown that a large extent of the
variation of urinary concentration of androgen glucuronides can
be ascribed to genetic variation in (UGTs). A CNV of UGT2B17 is
strongly associated with testosterone-glucuronide concentrations
in urine, both at baseline (15) and after the administration of a
supra-physiological dose of testosterone (16).
Here we aim to investigate if SULT2A1 display variation in
copy numbers in a Swedish population, and if there is an associa-
tion with SULT1A1 and SULT2A1 CNV genotype and the urinary
excretion of different androgen sulfates prior to and after the
administration of testosterone.
MATERIALS AND METHODS
SUBJECTS AND DESIGN
Study subjects included 30 healthy male volunteers aged 18–
50 years. The study population has been described in more detail
elsewhere (16). All participants gave informed consent consistent
with the approval of the Ethics Review Board, Karolinska Insti-
tutet, Stockholm. The participants were given 500 mg testosterone
www.frontiersin.org July 2013 | Volume 4 | Article 88 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schulze et al. SULT2A1 CNV and steroid sulfates
enanthate as a single intra muscular (i.m) dose of Testoviron
Depot (kindly provided by Schering Nordiska AB, Solna, Sweden)
equivalent to 360 mg testosterone. Urine samples were collected
for analyses before administration (day 0) and on days 1–9, 11,
13, and 15 after dose. All samples were collected between 07:00
and 11:00 h. Adverse drug reactions were monitored during the
study period. No major adverse drug reactions were registered.
No follow-up was needed. The study was conducted according
to the Helsinki Declaration and the ICH Harmonized Tripartite
Guideline for Good Clinical Practice.
URINARY ANALYSIS
The concentrations of sulfated androgens were analyzed using a
LC-MS/MS method as previously described (10). Briefly, 1 mL
and 20 lL ISTD samples were added to SPE Oasis HLB 96-well
plates and washed with 0.1% acetic acid, 0.1% ammonia, and 10%
MeOH. The analytes were eluted with acetone and after evap-
oration the residue was reconstituted with 20% MeOH. Waters
Acquity ultra performance liquid chromatographic (UPLC) sys-
tem was used to perform the separation on Waters Acquity
UPLC BEH RP18 column 50 9 2.1 mm with 1.7 lm particles.
The mobile phases were 5 mM NH4Ac adjusted by ammonia
to pH 9.6 (A) and MeOH (B). A Waters Micromass Quattro
Premier triple-quadrupole instrument (Waters Associates, Man-
chester, UK) operating with fast polarity switching in multiple
reaction mode (MRM) was used to detect the target analytes.
SULT1A1 AND SULT2A1 GENE COPY NUMBER VARIATION
Genomic DNA was extracted from 200µL blood using Qiagen
Mini Kit. Twenty nanograms genomic DNA was used in each
reaction together with 2X TaqMan Universal Master Mix (Applied
Biosystems, Foster City, CA, USA). The SULT1A1 and SULT2A1
CNV polymorphisms were analyzed by real-time polymerase
chain reaction analysis using premade assays Hs04461762_cn and
Hs03013147_cn (Applied Biosystems). Expression of albumin was
quantified as an endogenous control as described (17). Both reac-
tions were run in 15µL reactions. The PCR profile consisted of an
initial denaturation step at 95°C for 10 min followed by 40 cycles
of 92°C for 15 s and 60°C for 1 min.
DATA EVALUATION
Integration, calibration, and data evaluation was performed by
the TargetLynx software (Waters Associates, Manchester, UK).
The between subject variation in urine dilution was corrected
for by dividing the concentration values by the urinary creati-
nine (cr) concentration, which was determined by colorimetric
analysis (DRI Creatinine-Detect Test; Thermo Fisher Scientific,
Waltham, MA, USA). The areas under the curve (AUC) of the
different urinary steroids were calculated using the trapezoidal
rule. Statistical analyses were performed by Kruskal Wallis fol-
lowed by Dunn’s Multiple Comparison Test, since the data were
not normally distributed.
RESULTS
GENE COPY NUMBER ANALYSIS
The distribution of SULT1A1 copy numbers were; individuals
with one gene copy (i.e., one deletion) N = 6 (20%), two copies
N = 16 (53%), and three copies N = 8 (26%), respectively. The
distribution of SULT2A1 copy numbers were; individuals with
one copy N = 7 (23%), two copies N = 9 (60%), and three gene
copies N = 4 (13%), respectively.
SULT1A1 AND SULT2A1 CNV AND URINARY BASELINE LEVELS OF
STEROID SULFATES
There was a significant correlation between urinary concentra-
tion of DHEAS (p= 0.02) and androsteroneS (p= 0.01) and the
number of SULT2A1 CNV, Figures 1A,B. Individuals displaying
one SULT2A1 gene copy excreted lower levels of DHEAS and
androsteroneS (8.8 and 22.9 ng/µmol cr) compared to individuals
with two copies (44.5 and 53.6 ng/µmol cr) and three SULT2A1
gene copies (48.5 and 60.1 ng/µmol cr). There were no significant
correlation between SUL2A1 CNV and urinary concentration of
testosteroneS and etiocholanoloneS, Figures 1C,D. There was no
significant association between SULT1A1 CNV and urinary levels
of any androgen sulfates investigated.
SULT2A1 CNV AND URINARY AUC OF STEROID SULFATES POST
TESTOSTERONE ADMINISTRATION
The mean AUC for DHEAS during 15 days post dose were 44.5,
279, and 300 ng/µmol cr in individuals with one, two, and three
gene copies, respectively (p= 0.046), Figure 2A. The mean AUC
for testosteroneS during 15 days were 2.2, 7.4, and 11.6 nmol/µmol
cr in individuals with one, two, and three gene copies, respectively
(p= 0.019), Figure 2B. There were no significant correlations
between urinary AUC for etiocholanoloneS, androsteroneS, and
SULT2A1 CNV, Figures 2C,D.
There were no significant association between SULT1A1 CNV
and urinary AUC of androgen sulfates investigated.
DISCUSSION
Piper et al. showed that there is a large inter-individual variation
(500-fold) in the urinary excretion rate of DHEAS (11). However,
there are no studies investigating the inter-individual variability
of urinary levels of DHEAS in relation to genotype. We show
for the first time that SULT2A1 CNV is functional and that the
number of SULT2A1 copies is associated with the baseline con-
centration of DHEAS, as well as the baseline concentration of the
DHEA metabolite androsterone. In vitro studies have shown that
in addition to DHEA, SULT2A1 also possesses high sulfation activ-
ity toward androsterone (4). There was lower sulfation activity in
individuals with one SULT2A1 copy compared to individuals with
two or more copies for all steroid metabolites investigated except
etiocholanoloneS. Our results demonstrate that SULT2A1 exerts
activity not only toward DHEA but also toward several DHEA
metabolites in vivo.
After administration of exogenous testosterone to healthy vol-
unteers, the urinary excretion rate of sulfate metabolites was
significantly associated with SULT2A1 CNV. The urinary con-
centration of DHEAS and testosteroneS decreased approximately
50 and 80% respectively, after the administration of testosterone
enanthate. This is probably a result of a feedback mechanism on
the hypothalamic-pituitary axis. However, a significant SULT2A1
genotype association with the excretion of both DHEAS and
testosteroneS, even at the low concentrations observed post dose
further strengthen the finding that DHEA and testosterone are
substrates of SULT2A1 in vivo. On the other hand the urinary
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FIGURE 1 |The mean urinary concentration of (A) DHEAS (B)
androsteroneS (C) testosteroneS and (D) etiocholanoloneS in different
SULT2A1 genotype panels. The androgen conjugate concentration was
normalized against creatinine (cr) concentration. Individuals with two and
three SULT2A copy number variation excrete higher levels of DHEAS and
androsteroneS.
FIGURE 2 | Urinary (A) DHEAS (B) testosteroneS (C) etiocholanoloneS and (D) androsteroneS excretion (ng/µmol) for 15days in the different
SULT2A1 genotype groups after an i.m injection of 500mg testosterone enanthate.
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levels of the testosterone metabolites androsteroneS and etio-
cholanoloneS increased as a result of the administrated testos-
terone. The association between CNV of SULT2A1 and AUC of
androsteroneS was not statistically significant. However as the
study sample was small with only seven individuals with one gene
copy, the power might have been insufficient to demonstrate any
significance. Our AUC results are in agreement with our baseline
finding, supporting that these androgen metabolites are sulfated
by SULT2A1 in vivo.
The allele distribution of SULT1A1 was in agreement with
a previous study reporting a 25% frequency of three SULT1A1
copies in Caucasians (13) but opposite to other studies reporting
a 5% occurrence of one copy number (13, 18). There was no cor-
relation between CNV of SULT1A1 and the urine concentration
of the steroid sulfates. Even though SULT1A1 has been shown to
be involved in hormone metabolism, this enzyme has been shown
to be more important in the sulfation of estrogens (2).
For ethical and medical reason, testosterone was administered
to men only. Sulfation of androgens are important also in women,
and genetic variation in different SULTs have been associated with
altered risk for PCOS and breast cancer treatment (19, 20) and it
would be of interest to study this functional CNV in relation to the
metabolism of endogenous and exogenous androgens in females
in future studies.
DHEAS is found at high concentrations in the circulation
and has in addition to hormone related cancers and PCOS also
been shown to be involved in the risk of cardiovascular diseases
(21, 22). SULT2A1 expression is down-regulated in hepatocellular
carcinoma and correlated with higher grade and stage of cancer
(23). Additionally, SULT2A1 has been shown to be involved in the
metabolism and activation of carcinogenic compounds and drugs
(24, 25). It is possible that SULT2A1 CNV polymorphism may con-
tribute to individual variation in response to drugs that undergo
sulfation as well as altered risk for cancer and other diseases.
Variability in CNV is a common phenomenon in the human
genome, and has been observed for a number of enzymes involved
in biotransformation, i.e., UGT2B17, CYP2D6, and GSTM (26).
This is the first time SULT2A1 CNV has been studied in a
human population, and our results confirm that this puta-
tive polymorphism exists. According to the provider (Applied
Biosystems) of the SULT2A1 gene copy assay used in this study
the deletion consists of 2849 bp at the 3′-end of the SULT2A1
gene, at chromosome position 19q13.33. Jung et al. identified
a 150 000 bp homozygous SULT2A1 gene deletion at position
19q13.32 in a pulmonary inflammatory myofibroblastic tumor
(27). It is possible that different CNV exists throughout the
SULT2A1 gene. Further studies are warranted in order to char-
acterize the genetic make-up of this CNV and the phenotypic
consequences.
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